Expertise
____________________
We are experts in ophthalmics
We constantly evolve and improve, aiming to lead the way and enhance the quality of people’s lives. We invest in difficult-to-make, complex pharmaceutical products and offer partnership opportunities to grow your business mainly in the field of Ophthalmology.
Opthalmics 
______________________
Opthalmology is the core therapeutic area for RAFARM
Active ophthalmic licenses
80% of developments are ophthalmics
We specialize in the development and production of sterile ophthalmic pharmaceutical products in different formulations: Solutions, Suspensions, Nano-emulsions, Combination products
Injectables 
_______________________
Expertise in complex injectable products
Active licenses for injectables
We are experts in the development and production of complex injectable products (in ampoules and vials) and have established a diversified product pipeline to meet patients’ needs in different formulations: Solutions, Colloidal formulations, Nanomedicines
Value Added Medicines
__________________________
Value Added Medicines add incremental innovation to known molecules and deliver relevant improvement for patients, healthcare professionals and/or payers. To combine new technologies with known molecules requires considerable R&D investment and effort, that is why we dedicate annually, 20% of our R&D resources for the development of Value Added Medicines.
At RAFARM, we see opportunities in adding incremental innovation to known molecules and we invest in developing fixed combinations to improve treatment adherence, or medicine reformulation to offer patients new ways to administer their own treatments, or medicine repositioning to find new indications to address unmet medical need.
We are driven by knowledge that is turned into power
Every day in our laboratories, our team of scientists builds new scientific paths and enhance our expertise and know-how in the development and production of complex pharmaceutical products, in particular ophthalmics and injectables.
own development
pharmaceutical products
active product licenses
%
of net turnover
invested in R&D
>100
own development
pharmaceutical products
>1,100
active product licenses
13%
of net turnover
invested in R&D